Researchers evaluated the effectiveness of the BNT162b2 vaccine against the new SARS-CoV-2 variant of concern, Omicron, in five to 11-year-old children of Ontario, Canada.
This study examines hospitalizations and deaths associated with the SARS-CoV-2 Omicron variant compared with matched patients infected with the Delta variant.